GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Gilead Sciences Inc (LIM:GILD) » Definitions » Research & Development

Gilead Sciences (LIM:GILD) Research & Development : $5,719 Mil (TTM As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Gilead Sciences Research & Development?

Research & Development is the aggregate amount of research and development expenses during the year. Gilead Sciences's Research & Development for the three months ended in Dec. 2023 was $1,408 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2023 was $5,719 Mil.

Gilead Sciences Research & Development Historical Data

The historical data trend for Gilead Sciences's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gilead Sciences Research & Development Chart

Gilead Sciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4,055.00 5,039.00 4,601.00 4,977.00 5,718.00

Gilead Sciences Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1,152.00 1,447.00 1,407.00 1,457.00 1,408.00

Gilead Sciences Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $5,719 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Gilead Sciences  (LIM:GILD) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Gilead Sciences Research & Development Related Terms

Thank you for viewing the detailed overview of Gilead Sciences's Research & Development provided by GuruFocus.com. Please click on the following links to see related term pages.

Gilead Sciences (LIM:GILD) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Gilead Sciences Inc (LIM:GILD) » Definitions » Research & Development
Comparable Companies
BMY BIIB AMGN PFE OGN AMRN SCLX MIRA ABBV MRK LLY JNJ LSE:AZN XSWX:ROG XSWX:NOVN XPAR:SAN LSE:GSK TSE:4519 TSE:4568 SHSE:600276
Traded in Other Exchanges
GILD:USA GILD:Mexico GILD:Italy GISd:UK 0QYQ:UK GIS:Germany GILD34:Brazil GILD:Austria GILD:Argentina
Address
333 Lakeside Drive, Foster, CA, USA, 94404
Website
https://www.gilead.com
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.